Patents by Inventor Albert George Thom

Albert George Thom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Blood brain barrier transport molecules and uses thereof
    Patent number: 10184008
    Abstract: The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 22, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Carl Innes Webster, Albert George Thom, Lutz U Jermutus, Jonathan P Hatcher
  • BLOOD BRAIN BARRIER TRANSPORT MOLECULES AND USES THEREOF
    Publication number: 20180057605
    Abstract: The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.
    Type: Application
    Filed: December 18, 2015
    Publication date: March 1, 2018
    Inventors: Carl Innes WEBSTER, Albert George THOM, Lutz U JERMUTUS, Jonathan P HATCHER
  • Methods of treating neuropathic pain with specific binding members for NGF
    Patent number: 9701746
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: July 11, 2017
    Assignee: MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • Specific Binding Members for NGF
    Publication number: 20160297878
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 13, 2016
    Applicant: MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • Specific binding members for NGF
    Patent number: 9315571
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: April 19, 2016
    Assignees: Elan Pharma International Limited, MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • Polypeptide Variants
    Publication number: 20100184959
    Abstract: The present invention relates to methods for selecting, obtaining or producing Fc variant polypeptides which show altered recognition for an Fc ligand (e.g., Fc?R, CIq). Additionally, the Fc variant polypeptides may have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variant polypeptides particularly for therapeutic purposes.
    Type: Application
    Filed: March 19, 2008
    Publication date: July 22, 2010
    Applicant: MEDIMMUNE LIMITED
    Inventors: Gulin Guler-Gane, Robert George Edward Holgate, Lutz Ulrich Jochen Wilhelm Jermutus, Jacqueline Michaela Levens, John Norman Lund, Ross Anthony Stewart, Albert George Thom, Carl Innes Webster